Guardian Pharmacy Services reported first-quarter 2026 revenue of $336.6 million, up 2% year over year, despite significant pricing pressure from the Inflation Reduction Act's new framework. CEO Fred Burke said the company experienced approximately 60% price declines on IRA-selected drugs, noting that revenue would have grown by low double digits without these government-mandated reductions. The company reported gross profit of $76 million, up 19% year over year, with adjusted EBITDA rising 27% to $29.8 million. Total residents increased 10% to approximately 207,000, with script volumes also up 10%. CFO David Morris attributed growth to organic expansion, acquisitions and plan optimisation efforts. Guardian raised its adjusted EBITDA guidance whilst maintaining its full-year revenue outlook following the quarter.

Guardian Pharmacy Services reported 2% revenue growth in Q1 2026, offsetting a 60% decline in branded drug pricing from the Inflation Reduction Act through renegotiated payer contracts. The company updated full-year adjusted EBITDA guidance to $123 million–$127 million, reflecting a $3 million discrete first-quarter benefit. Underlying fundamentals remained strong, with 10% year-over-year growth in resident count and prescription volumes. However, operational complexity increased due to Medicare's new Transaction Facilitator platform, causing working capital timing shifts expected to normalise throughout the year. Results included $3.2 million in legal expenses for reimbursement advocacy, with an $8.5 million settlement to be recognised in Q2. Recent acquisitions dampened margins by 80 basis points. Management expects labour costs to rise modestly as the company invests in regional leadership whilst maintaining its acquisition pace.

Guardian Pharmacy Services has priced a follow-on offering at $21 per share, raising approximately $181 million in a synthetic secondary. The offering price represents a 35% discount to the previous closing price of $32.59, though the stock had already declined 2.60% over the past month. The company reported strong 2025 results, with revenue of $1.45 billion (up 18%) and adjusted EBITDA of $115.1 million (up 53%). Management raised 2026 EBITDA guidance to $120–$124 million, but revenue projections remain flat at $1.40–$1.42 billion, signalling a growth slowdown. Guardian's shares trade at a trailing P/E of 55.19, with a market capitalisation near $2.20 billion. Analysts rate the stock a moderate buy with a price target around $32, indicating limited upside as the market has absorbed recent earnings surprises.